Gland Pharma Secures Major CDMO Agreement with Potential of $90–100 Million in Annualized Revenue

Gland Pharma has entered into a strategic Manufacturing and Supply Agreement (MSA) with a leading, undisclosed global pharmaceutical company to serve as an end-to-end Contract Development and Manufacturing Organization (CDMO) for sterile injectable products. Key Deal Highlights: Scope of Work: Comprehensive "one-stop" solution covering technology transfer, process development, scale-up, validation, and long-term commercial manufacturing. Product Portfolio: 55 Stock Keeping Units (SKUs) spanning both oncology and non-oncology products, delivered in complex presentations including Vials, Lyophilized (Lyo), Ampoules, and Pre-filled Syringes (PFS). Capacity: Production will be distributed across three of Gland Pharma’s manufacturing sites. Financial Impact: Estimated annualized revenue potential of USD 90–100 million once fully commercialized. Timeline: Technology transfer is expected to be completed within two years, with revenue generation slated to commence in Calendar Year 2029. Strategic Rationale: CDMO Expansion: This agreement solidifies Gland Pharma’s transition into a full-service, integrated CDMO partner, moving beyond traditional contract manufacturing to include high-value development and technology transfer services. Focus on Complex Formulations: The inclusion of oncology products and pre-filled syringes highlights a strategic focus on technically demanding, higher-margin sterile injectables rather than conventional low-margin generics. Outlook: While revenue realization is deferred until 2029, this multi-year agreement provides exceptional long-term top-line visibility and ensures high capacity utilization across Gland’s manufacturing network. It strongly validates the company’s global quality standards and development capabilities, positioning it for sustained growth in the highly lucrative global CDMO market. $GLAND